🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Diagnosis and classification of myelodysplastic syndromes loom.ly/pqtwDkM #myeloidneoplasia #reviewarticles #reviewseries

Just to add to this amazing thread by Nicolas Duployez on the complexities of molecular analysis of #CEBPA, this is what popped up in reporting today (57Y/M, 54% blast on morphology, AML by flow): Nikhil Patkar Sweta Rajpal Pgs_mani Prashant Tembhare

Out in @BloodJournal ⬇️⬇️ 🔹UBTF tandem duplications and KMT2A/menin complex co-occupy genomic targets dysregulated in UBTF-TD acute myeloid leukemias. 🔹UBTF-TD acute myeloid leukemias are sensitive to menin inhibition. #leusm OncoAlert

x.com/NicolasDuploye…

Les patriarches hospitalo-U qui ne jurent que par leur H-index sont le cancer de la profession : Lettre hallucinante de l'ANPGM qui demande à ce que la loi ne soit pas appliquée car des personnes sans le diplôme veulent apparaître sur les compte rendus !!

ELN-risk classification for #AMLsm patients receiving less-intensive therapies (ELN 2024 Less-Intensive) ashpublications.org/blood/article/…

📍ELN 2017/2022 prognostic classifiers did not adequately stratify OS outcomes for #AMLsm patients treated with VEN-based regimens. 📍A 4-gene prognostic model (TP53, FLT3-ITD, NRAS, and KRAS) stratified OS outcomes with VEN-AZA treatment in #AMLsm. ashpublications.org/blood/article/…

Previous studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at NatureGen! 🎉🎈🍾 nature.com/articles/s4158…

#HappyNewYear2025 #Hematology Proud of our team at CHU de Lille , dedicated to the molecular biology of hematological malignancies, who gave their best throughout 2024. THANKS to all of you! 🙌 Ready to take on new challenges in 2025!

PFMG2025–integrating genomic medicine into the national healthcare sys... sciencedirect.com/science/articl…

Service note📢: Higher sensitivity doesn’t mean better test BUT it changes the question you can ask. 🔬 MRD-POS vs MRD-NEG isn’t enough to use #MRD to guide therapy (e.g., recommend or avoid HSCT). It's all about the threshold. #leusm #AMLsm

Very happy to share our work on therapy-related myeloid neoplasms (t-MN) post-CD19 CAR T-cell therapy, published in Leukemia Journal and involving 4 French centers (CHU de Lille, Lyon, Caen, St-Étienne). 🔗 doi.org/10.1038/s41375… #CAR_T #Lymphoma #tMN #Hematology

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia Blood Cancer Journal nature.com/articles/s4140…

🩸 IDH1/2 mutations in intensively treated #AML: ➡️ NPM1 & DNMT3A co-mutations drive prognosis. ➡️ IDH1/2 persistence in remission does not predict progression. #leusm #AMLsm 🎉⁦Fenwarth Laurène⁩ nature.com/articles/s4140…

Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults 👉enriched in NPM1 (FLT3wt) and UBTF mutations. 🔬🧬Morphology guides, but mutations define the diagnosis of AML. #leusm #AMLsm Fenwarth Laurène Benjamin Podvin onlinelibrary.wiley.com/doi/10.1111/ej…